CeeD (Centre Européen d'étude du diabète)
3
1M
1
0.10
0.67
- Areas of investment
Summary
CeeD (Centre Europu00e9en d'u00e9tude du diabu00e8te) is the famous Corporate Investor, which was founded in 1991.
The usual cause for the fund is to invest in rounds with 3 partakers. Despite the CeeD (Centre Europu00e9en d'u00e9tude du diabu00e8te), startups are often financed by Statice, Emertec Gestion, CTTM. The meaningful sponsors for the fund in investment in the same round are Emertec Gestion, CTTM, Statice. In the next rounds fund is usually obtained by Emertec Gestion, Cap Innov'Est, CTTM.
The important activity for fund was in 2011. The fund is constantly included in less than 2 deals per year. The usual things for fund are deals in the range of 1 - 5 millions dollars.
Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund. Among the most popular fund investment industries, there are Medical Device, Diabetes. Among the most popular portfolio startups of the fund, we may highlight Defymed.
Investments analytics
Analytics
- Total investments
- 3
- Lead investments
- 0
- Rounds per year
- 0.10
- Follow on index
- 0.67
- Investments by industry
- Medical Device (3)
- Diabetes (3)
- Investments by region
-
- France (3)
- Peak activity year
- 2011
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 11
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Defymed | 04 Oct 2013 | Medical Device, Diabetes | Seed | 1M | Grand Est, Strasbourg, France |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.